These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 11948143

  • 1. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A.
    Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model.
    Smith MR, Xie T, Zhou ZZ, Joshi I.
    Clin Cancer Res; 2001 Feb; 7(2):400-6. PubMed ID: 11234896
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.
    Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G.
    Oncogene; 1994 Oct; 9(10):3049-55. PubMed ID: 8084613
    [Abstract] [Full Text] [Related]

  • 4. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
    Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A.
    Cancer Gene Ther; 1995 Sep; 2(3):207-12. PubMed ID: 8528964
    [Abstract] [Full Text] [Related]

  • 5. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines.
    Capaccioli S, Quattrone A, Schiavone N, Calastretti A, Copreni E, Bevilacqua A, Canti G, Gong L, Morelli S, Nicolin A.
    Oncogene; 1996 Jul 04; 13(1):105-15. PubMed ID: 8700536
    [Abstract] [Full Text] [Related]

  • 6. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Aug 04; 7(8):2537-44. PubMed ID: 11489837
    [Abstract] [Full Text] [Related]

  • 7. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May 04; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 8. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [Abstract] [Full Text] [Related]

  • 9. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T, Jedlicková K, Kriegová E, Jarosová M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K.
    Neoplasma; 2001 Jun 15; 48(6):501-5. PubMed ID: 11949845
    [Abstract] [Full Text] [Related]

  • 10. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
    Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B.
    J Mol Med (Berl); 2001 Oct 15; 79(10):587-93. PubMed ID: 11692156
    [Abstract] [Full Text] [Related]

  • 11. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1.
    Denyssevych T, Lestou VS, Knesevich S, Robichaud M, Salski C, Tan R, Gascoyne RD, Horsman DE, Mayer LD.
    Leukemia; 2002 Feb 15; 16(2):276-83. PubMed ID: 11840295
    [Abstract] [Full Text] [Related]

  • 12. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 15; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 13. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA.
    Clin Cancer Res; 2006 Aug 15; 12(16):4940-8. PubMed ID: 16914583
    [Abstract] [Full Text] [Related]

  • 14. Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line.
    Morelli S, Alama A, Quattrone A, Gong L, Copreni E, Canti G, Nicolin A.
    Anticancer Drug Des; 1996 Jan 15; 11(1):1-14. PubMed ID: 8639245
    [Abstract] [Full Text] [Related]

  • 15. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF, de Paus RA, Kluin-Nelemans HC, Kluin PM, van Bergen CA, Munro AJ, Hale G, Willemze R, Falkenburg JH.
    Exp Hematol; 1996 Jul 15; 24(8):919-26. PubMed ID: 8690051
    [Abstract] [Full Text] [Related]

  • 16. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C.
    Clin Cancer Res; 2005 Mar 01; 11(5):1990-8. PubMed ID: 15756025
    [Abstract] [Full Text] [Related]

  • 17. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A.
    Clin Cancer Res; 2007 Apr 01; 13(7):2226-35. PubMed ID: 17404107
    [Abstract] [Full Text] [Related]

  • 18. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 19. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 01; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 20. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB.
    Clin Cancer Res; 2004 Nov 15; 10(22):7662-70. PubMed ID: 15569999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.